Fly News Breaks for February 10, 2020
Feb 10, 2020 | 07:12 EDT
H.C. Wainwright analyst Yi Chen raised the firm's price target on Ocular Therapeutix to $8 from $6 after the company Friday presented data from the Phase 1 trial of OTX-TIC in patients with primary open angle glaucoma or ocular hypertension. Given the positive data thus far, the analyst increased the probability of approval for OTX-TIC to 30% from 20%. Chen reiterates a Buy rating on the shares.
News For OCUL From the Last 2 Days
There are no results for your query OCUL